• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Albenza (albendazole)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Albenza (albendazole)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Albenza has been approved for the treatment of two parasitic infections caused by worms:

    • Hydatid cyst disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus
    • Neurocysticercosis caused by larval forms of the pork tapeworm, Taenia solium

    For hydatid disease, the recommended dose for Albenza is 400 mg twice daily with meals for three cycles (each cycle consists of 28 days of dosing followed by a 14-day albendazole-free interval). For neurocysticercosis, the recommended dose is 400 mg twice daily for eight to 30 days.

    Albendazole was first marketed outside the United States in 1982 for human use where it is currently marketed under the trade names of Zentel and Eskazole.

    Clinical Results

    Subjects treated with Albenza have shown improvement in more than 80% of the neurocysticercosis subjects and cure or improvement in up to 70%of the hydatid subjects.

    Side Effects

    Side effects were usually mild and resolved without treatment. The most frequently reported side effects by hydatid disease subjects included abnormal liver function, abdominal pain, nausea and vomiting; those reported by neurocysticercosis subjects included headache, nausea, and vomiting.

    Additional Information

    E. granulosus is considered endemic in the Western US sheep-raising areas of Utah, Arizona, and Nevada, but the vast majority of cases occur in new immigrants who have been exposed to the infection years previously in their countries of origin, or in travelers from the United States to endemic areas. Most cysts are found in the liver where, after remaining asymptomatic for decades, they finally produce abdominal pain or a mass. The incidence of hydatid disease in the United States is estimated to be between 100 and 200 new cases diagnosed annually.

    T. solium cysticercosis is rare in the United States except in immigrants from endemic areas. It is most common in Latin America, Asia, Russia, and Eastern Europe and is caused by inadequately cooked or raw infected pork. Infection with the adult worm is usually asymptomatic. Severe larval infection, a result of ingestion of contaminated material, may cause muscle pains, weakness, or fever. It can also cause epileptic seizures. The incidence of neurocysticercosis is estimated to be less than 1,000 new cases diagnosed annually.

    Worldwide, the prevalence of hydatid disease is estimated to be about one million people mostly found in herding and animal-raising countries and regions of North West China, parts of Northern and Southern Africa, East Africa, Iraq, the Mediterranean basin, Uruguay, Argentina, and Chile. It also occurs occasionally in other countries including the United States, Great Britain, South and East Europe, Australia, and New Zealand. The prevalence of neurocysticercosis is estimated to be about 1.5 million people worldwide. In both diseases, infection with the larva is accidental and transmission from human-to-human does not normally occur.

    Approval Date: 1996-06-01
    Company Name: SmithKline Beecham
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing